← Leaderboards
Garth Powis
University Of Arizona
$46,106,518
Attributed
$46,106,518
Total exposure
37
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$93,589,178 · 40
By mechanism
P30$40,796,706 · 12
R01$22,263,990 · 10
U19$13,633,471 · 7
U54$7,241,185 · 2
P01$3,407,353 · 2
P50$2,501,342 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Arizona
Same institution · by research overlap
- Robert T Dorr$3,942,329
- Alison T Stopeck$4,717,705
- Tomislav Dragovich$3,140,335
- Gregory R J Thatcher$19,556,155
- Richard S Glass$2,365,269
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMalignant NeoplasmsTumorCancer TherapyInhibitor/AntagonistGrantLeadSmall MoleculeCancer CenterProgramsGrowthAreaCancer CellNovel TherapeuticsCancer Center Support GrantResponseNeoplasm MetastasisSignal TransductionResearch PersonnelPharmaceutical PreparationsMemberStressSignal PathwayFaculty
Grant awards (181)
Clinical evaluation of a novel AKT/PDK1 inhibitor, PHT-427, for the treatment of multi-field actinitc keratoses$2,085,765
R44 · FY2025 · CA · contact PI
Developmental Funds$781,775
P30 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$504,147
P30 · FY2023 · CA · contact PI
Cancer Research Career Enhancement and Related Activities (CRCERA)$61,425
P30 · FY2023 · CA · contact PI
Admin Core$32,070
P30 · FY2023 · CA · contact PI
Developmental Funds$781,775
P30 · FY2022 · CA · contact PI
Leadership, Planning and Evaluation$504,147
P30 · FY2022 · CA · contact PI
Inhibiting Multi-Functional ALDOA for Cancer Therapy$498,144
R01 · FY2022 · CA · contact PI
Cancer Research Career Enhancement and Related Activities (CRCERA)$61,425
P30 · FY2022 · CA · contact PI
Admin Core$32,070
P30 · FY2022 · CA · contact PI
Inhibiting Multi-Functional ALDOA for Cancer Therapy$504,587
R01 · FY2021 · CA · contact PI
Targeting ERK5 for Colorectal Cancer Therapy$169,469
R21 · FY2021 · CA · contact PI
Developmental Funds$781,775
P30 · FY2020 · CA · contact PI
Inhibiting Multi-Functional ALDOA for Cancer Therapy$631,803
R01 · FY2020 · CA · contact PI
Leadership, Planning and Evaluation$504,147
P30 · FY2020 · CA · contact PI
Admin Core$487,500
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant (CCSG)$487,500
P30 · FY2020 · CA · contact PI
Targeting ERK5 for Colorectal Cancer Therapy$273,488
R21 · FY2020 · CA · contact PI
Cancer Center Support Grant (CCSG)$100,000
P30 · FY2020 · CA · contact PI
Admin Core$100,000
P30 · FY2020 · CA · contact PI
Cancer Research Career Enhancement and Related Activities (CRCERA)$61,425
P30 · FY2020 · CA · contact PI
Admin Core$32,070
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant (CCSG)$3,887,448
P30 · FY2019 · CA · contact PI
Developmental Funds Core$868,714
P30 · FY2019 · CA · contact PI
Inhibiting Multi-Functional ALDOA for Cancer Therapy$612,848
R01 · FY2019 · CA · contact PI
PLEKHA7 A Novel Target for Mutant KRAS Therapy$605,409
R01 · FY2019 · CA · contact PI
Administration (Admin Core)$437,433
P30 · FY2019 · CA · contact PI
Cancer Targets and Drug Discovery$240,550
T32 · FY2019 · CA · contact PI
Administration (Admin Core)$187,734
P30 · FY2019 · CA · contact PI
Cancer Center Support Grant (CCSG)$187,734
P30 · FY2019 · CA · contact PI
Cancer Center Support Grant (CCSG)$146,250
P30 · FY2019 · CA · contact PI
Planning and Evaluation Core$68,599
P30 · FY2019 · CA · contact PI
PLEKHA7 A Novel Target for Mutant KRAS Therapy$12,125
R01 · FY2019 · CA · contact PI
Cancer Center Support Grant (CCSG)$3,887,448
P30 · FY2018 · CA · contact PI
Developmental Funds Core$868,714
P30 · FY2018 · CA · contact PI
Inhibiting Multi-Functional ALDOA for Cancer Therapy$655,553
R01 · FY2018 · CA · contact PI
PLEKHA7 A Novel Target for Mutant KRAS Therapy$624,131
R01 · FY2018 · CA · contact PI
Administration (Admin Core)$437,433
P30 · FY2018 · CA · contact PI
Cancer Targets and Drug Discovery$232,666
T32 · FY2018 · CA · contact PI
Cancer Center Support Grant (CCSG)$199,044
P30 · FY2018 · CA · contact PI
Cancer Center Support Grant (CCSG)$146,250
P30 · FY2018 · CA · contact PI
PLEKHA7 A Novel Target for Mutant KRAS Therapy$82,787
R01 · FY2018 · CA · contact PI
Planning and Evaluation Core$68,599
P30 · FY2018 · CA · contact PI
Developmental Funds Core$12,441
P30 · FY2018 · CA · contact PI
Planning and Evaluation Core$12,441
P30 · FY2018 · CA · contact PI
Administration (Admin Core)$12,441
P30 · FY2018 · CA · contact PI
Planning and Evaluation Core$9,142
P30 · FY2018 · CA · contact PI
Administration (Admin Core)$9,142
P30 · FY2018 · CA · contact PI
Developmental Funds Core$9,141
P30 · FY2018 · CA · contact PI
Cancer Center Support Grant (CCSG)$3,887,448
P30 · FY2017 · CA · contact PI
Developmental Funds Core$868,715
P30 · FY2017 · CA · contact PI
PLEKHA7 A Novel Target for Mutant KRAS Therapy$624,131
R01 · FY2017 · CA · contact PI
Administration (Admin Core)$437,434
P30 · FY2017 · CA · contact PI
Oncogene Addiction Biomarkers for a KRAS Therapy$212,063
R21 · FY2017 · CA · contact PI
Cancer Center Support Grant (CCSG)$131,625
P30 · FY2017 · CA · contact PI
PLEKHA7 A Novel Target for Mutant KRAS Therapy$82,787
R01 · FY2017 · CA · contact PI
Planning and Evaluation Core$68,600
P30 · FY2017 · CA · contact PI
Cancer Center Support Grant (CCSG)$3,887,448
P30 · FY2016 · CA · contact PI
Developmental Funds Core$868,715
P30 · FY2016 · CA · contact PI
PLEKHA7 A Novel Target for Mutant KRAS Therapy$624,131
R01 · FY2016 · CA · contact PI
Administration (Admin Core)$437,435
P30 · FY2016 · CA · contact PI
Inhibiting oncogenic KRAS for cancer therapy$404,625
R01 · FY2016 · CA · contact PI
Exploiting tumor stroma interactions for cancer therapy$404,625
R01 · FY2016 · CA · contact PI
Oncogene Addiction Biomarkers for a KRAS Therapy$254,475
R21 · FY2016 · CA · contact PI
Cancer Center Support Grant (CCSG)$146,250
P30 · FY2016 · CA · contact PI
PLEKHA7 and beta-catenin interact to regulate mutant KRas$70,290
R01 · FY2016 · CA · contact PI
Planning and Evaluation Core$68,601
P30 · FY2016 · CA · contact PI
Cancer Center Support Grant (CCSG)$3,887,448
P30 · FY2015 · CA · contact PI
Developmental Funds Core$868,715
P30 · FY2015 · CA · contact PI
PLEKHA7 A Novel Target for Mutant KRAS Therapy$624,131
R01 · FY2015 · CA · contact PI
Administration (Admin Core)$437,435
P30 · FY2015 · CA · contact PI
Inhibiting oncogenic KRAS for cancer therapy$404,625
R01 · FY2015 · CA · contact PI
Exploiting tumor stroma interactions for cancer therapy$404,625
R01 · FY2015 · CA · contact PI
Cancer Center Support Grant (CCSG)$125,190
P30 · FY2015 · CA · contact PI
Planning and Evaluation Core$68,601
P30 · FY2015 · CA · contact PI
Cancer Center Support Grant$3,848,959
P30 · FY2014 · CA · contact PI
Exploiting tumor stroma interactions for cancer therapy$392,486
R01 · FY2014 · CA · contact PI
Inhibiting oncogenic KRAS for cancer therapy$392,486
R01 · FY2014 · CA · contact PI
Cancer Center Support Grant$141,863
P30 · FY2014 · CA · contact PI
Cancer Center Support Grant$3,710,081
P30 · FY2013 · CA · contact PI
Hypoxia and Anticancer Drug Action$400,039
R01 · FY2013 · CA · contact PI
Exploiting tumor stroma interactions for cancer therapy$380,348
R01 · FY2013 · CA · contact PI
Inhibiting oncogenic KRAS for cancer therapy$380,348
R01 · FY2013 · CA · contact PI
Redox Signaling and Cancer Drug Action$326,453
R01 · FY2013 · CA · contact PI
Cancer Center Support Grant$136,744
P30 · FY2013 · CA · contact PI
Hypoxia and Anticancer Drug Action$15,400
R01 · FY2013 · CA · contact PI
Redox Signaling and Cancer Drug Action$15,400
R01 · FY2013 · CA · contact PI
Hypoxia and Anticancer Drug Action$336,094
R01 · FY2012 · CA · contact PI
Inhibiting oncogenic KRAS for cancer therapy$327,850
R01 · FY2012 · CA · contact PI
Exploiting tumor stroma interactions for cancer therapy$327,850
R01 · FY2012 · CA · contact PI
Redox Signaling and Cancer Drug Action$274,271
R01 · FY2012 · CA · contact PI
MECHANISTIC TRANSLATIONAL STUDIES OF THE STRESS RESPONSE IN GASTROINTESTINAL CANC$498,978
P50 · FY2011 · CA · contact PI
MECHANISTIC AND TRANSLATIONAL STUDIES OF THE HYPOXIA RESPONSE IN CANCER$404,217
P01 · FY2011 · CA · contact PI
Hypoxia and Anticancer Drug Action$336,094
R01 · FY2011 · CA · contact PI
Chemoprevention by a Targeted Thioredoxin Inhibitor.$309,964
R01 · FY2011 · CA · contact PI
Redox Signaling and Cancer Drug Action$274,271
R01 · FY2011 · CA · contact PI
MECHANISTIC TRANSLATIONAL STUDIES OF THE STRESS RESPONSE IN GASTROINTESTINAL CANC$522,880
P50 · FY2010 · CA · contact PI
MECHANISTIC AND TRANSLATIONAL STUDIES OF THE HYPOXIA RESPONSE IN CANCER$416,664
P01 · FY2010 · CA · contact PI
Hypoxia and Anticancer Drug Action$346,489
R01 · FY2010 · CA · contact PI
Chemoprevention by a Targeted Thioredoxin Inhibitor.$319,550
R01 · FY2010 · CA · contact PI
Redox Signaling and Cancer Drug Action$282,753
R01 · FY2010 · CA · contact PI
Cancer Drugs Active Against Stress Signaling Pathways$1,064,087
U19 · FY2009 · CA · contact PI
MECHANISTIC TRANSLATIONAL STUDIES OF THE STRESS RESPONSE IN GASTROINTESTINAL CANC$511,402
P50 · FY2009 · CA · contact PI
Novel Inhibitors of Akt Signaling in Pancreatic Cancer$429,731
R01 · FY2009 · CA · contact PI
MECHANISTIC AND TRANSLATIONAL STUDIES OF THE HYPOXIA RESPONSE IN CANCER$408,468
P01 · FY2009 · CA · contact PI
Hypoxia and Anticancer Drug Action$346,489
R01 · FY2009 · CA · contact PI
Chemoprevention by a Targeted Thioredoxin Inhibitor.$319,550
R01 · FY2009 · CA · contact PI
Treatment of Hypoxia Resistance in Pancreatic Cancer -Lab$319,364
P01 · FY2009 · CA · contact PI
Redox Signaling and Cancer Drug Action$282,753
R01 · FY2009 · CA · contact PI
Novel Inhibitors of Akt Signaling in Pancreatic Cancer$60,439
R01 · FY2009 · CA · contact PI
Cancer Drugs Active Against Stress Signaling Pathways$1,084,734
U19 · FY2008 · CA · contact PI
MECHANISTIC TRANSLATIONAL STUDIES OF THE STRESS RESPONSE IN GASTROINTESTINAL CANC$510,268
P50 · FY2008 · CA · contact PI
Novel Inhibitors of Akt Signaling in Pancreatic Cancer$418,157
R01 · FY2008 · CA · contact PI
MECHANISTIC AND TRANSLATIONAL STUDIES OF THE HYPOXIA RESPONSE IN CANCER$396,516
P01 · FY2008 · CA · contact PI
Chemoprevention by a Targeted Thioredoxin Inhibitor.$319,550
R01 · FY2008 · CA · contact PI
Treatment of Hypoxia Resistance in Pancreatic Cancer -Lab$311,236
P01 · FY2008 · CA · contact PI
Novel Inhibitors of Akt Signaling in Pancreatic Cancer$69,745
R01 · FY2008 · CA · contact PI
Cancer Drugs Active Against Stress Signaling Pathways$1,019,295
U19 · FY2007 · CA · contact PI
MECHANISTIC TRANSLATIONAL STUDIES OF THE STRESS RESPONSE IN GASTROINTESTINAL CANC$457,814
P50 · FY2007 · CA · contact PI
Novel Inhibitors of Akt Signaling in Pancreatic Cancer$414,979
R01 · FY2007 · CA · contact PI
MECHANISTIC AND TRANSLATIONAL STUDIES OF THE HYPOXIA RESPONSE IN CANCER$369,702
P01 · FY2007 · CA · contact PI
Treatment of Hypoxia Resistance in Pancreatic Cancer -Lab$305,909
P01 · FY2007 · CA · contact PI
Thioredoxin Inhibition of Apoptosis and Cancer Treatment$269,170
R01 · FY2007 · CA · contact PI
Cancer Drugs Active Against Stress Signaling Pathways$1,073,461
U19 · FY2006 · CA · contact PI
HIF and Anticancer Drug Action$461,992
R01 · FY2006 · CA · contact PI
Novel Inhibitors of Akt Signaling in Pancreatic Cancer$415,914
R01 · FY2006 · CA · contact PI
Thioredoxin Inhibition of Apoptosis and Cancer Treatment$277,209
R01 · FY2006 · CA · contact PI
Treatment of Hypoxia Resistance in Pancreatic Cancer -Lab$240,699
P01 · FY2006 · CA · contact PI
Survival Signals for Molecular Target Assessment$191,340
U54 · FY2006 · CA · contact PI
Survival Signals for Molecular Target Assessment$1,495,253
U54 · FY2005 · CA
Cancer Drugs Active Against Stress Signaling Pathways$1,090,569
U19 · FY2005 · CA
HIF and Anticancer Drug Action$465,796
R01 · FY2005 · CA
Novel Inhibitors of Akt Signaling in Pancreatic Cancer$418,213
R01 · FY2005 · CA
Thioredoxin Inhibition of Apoptosis and Cancer Treatment$273,057
R01 · FY2005 · CA
Treatment of Hypoxia Resistance in Pancreatic Cancer -Lab$234,578
P01 · FY2005 · CA
EXPLOITING ADAPTIVE MECHANISMS TO HYPOXIC STRESS TO TREAT CANCER$102,268
U19 · FY2005 · CA
CELL LINE AND ANIMAL TESTING$58,723
U19 · FY2005 · CA
ADMINISTRATIVE CORE$45,305
U19 · FY2005 · CA
Thioredoxin Inhibition of Apoptosis and Cancer Treatment$11,763
R01 · FY2005 · CA
Survival Signals for Molecular Target Assessment$1,460,020
U54 · FY2004 · CA
ANTICANCER DRUGS ACTIVE AGAINST CELL CYCLE AND SIGNAL PA$1,316,121
U19 · FY2004 · CA
HIF and Anticancer Drug Action$337,088
R01 · FY2004 · CA
Thioredoxin Inhibition of Apoptosis and Cancer Treatment$284,820
R01 · FY2004 · CA
HIF and Anticancer Drug Action$125,397
R01 · FY2004 · CA
Survival Signals for Molecular Target Assessment$1,538,161
U54 · FY2003 · CA
ANTICANCER DRUGS ACTIVE AGAINST CELL CYCLE AND SIGNAL PA$1,293,918
U19 · FY2003 · CA
Hypoxia Inducible Factor and Anticancer Drug Action$337,088
R01 · FY2003 · CA
Thioredoxin Inhibition of Apoptosis and Cancer Treatment$284,820
R01 · FY2003 · CA
Survival Signals for Molecular Target Assessment$1,500,000
U54 · FY2002 · CA
ANTICANCER DRUGS ACTIVE AGAINST CELL CYCLE AND SIGNAL PA$1,294,032
U19 · FY2002 · CA
3 DEOXY INOSITOL LIPIDS AND CANCER GROWTH INHIBITION$441,385
R01 · FY2002 · CA
Phosphatidylinositol-3-kinase and Akt signaling targets$296,752
U54 · FY2002 · CA
CORE--PHARMACOKINETICS /PREFORMULATION$250,404
U19 · FY2002 · CA
CORE--CELL LINE AND ANIMAL TESTING$250,404
U19 · FY2002 · CA
ADAPTIVE IMMUNOTHERAPY--LONG-CIRCULATING MACROMOLECULES$250,404
U19 · FY2002 · CA
REDOX MECHANISMS IN COLORECTAL CANCER$0
P50 · FY2002 · CA
Survival Signals for Molecular Target Assessment$759,659
U54 · FY2001 · CA
ANTICANCER DRUGS ACTIVE AGAINST CELL CYCLE AND SIGNAL PA$646,525
U19 · FY2001 · CA
3 DEOXY INOSITOL LIPIDS AND CANCER GROWTH INHIBITION$430,073
R01 · FY2001 · CA
CORE--PHARMACOKINETICS /PREFORMULATION$250,404
U19 · FY2001 · CA
CORE--CELL LINE AND ANIMAL TESTING$250,404
U19 · FY2001 · CA
ADAPTIVE IMMUNOTHERAPY--LONG-CIRCULATING MACROMOLECULES$250,404
U19 · FY2001 · CA
THIOREDOXIN INHIBITION OF APOPTOSIS AND CANCER TREATMENT$230,032
R01 · FY2001 · CA
THIOREDOXIN REDUCTASES AND CANCER$220,460
R01 · FY2001 · CA
ANTICANCER DRUGS ACTIVE AGAINST CELL CYCLE AND SIGNAL PA$25,813
U19 · FY2001 · CA
CORE--CELL LINE AND ANIMAL TESTING$0
U19 · FY2001 · CA
Phosphatidylinositol-3-kinase and Akt signaling targets$0
U54 · FY2001 · CA
CORE--PHARMACOKINETICS /PREFORMULATION$0
U19 · FY2001 · CA
ADAPTIVE IMMUNOTHERAPY--LONG-CIRCULATING MACROMOLECULES$0
U19 · FY2001 · CA
CANCER DRUGS ACTIVE AGAINST SIGNAL TRANSDUCTION TARGETS$859,609
U19 · FY2000 · CA
ANTICANCER DRUGS ACTIVE AGAINST CELL CYCLE AND SIGNAL PA$825,333
U19 · FY2000 · CA
3 DEOXY INOSITOL LIPIDS AND CANCER GROWTH INHIBITION$419,271
R01 · FY2000 · CA
DNA MICROARRAY INSTRUMENTATION$276,655
S10 · FY2000 · RR
THIOREDOXIN INHIBITION OF APOPTOSIS AND CANCER TREATMENT$224,223
R01 · FY2000 · CA
THIOREDOXIN REDUCTASES AND CANCER$214,927
R01 · FY2000 · CA
CORE--CYTOTOXICITY TESTING &PHARMACOKINETICS OF POTENTIAL ANTICANCER DRUGS$165,627
U19 · FY2000 · CA
LIPID SIGNALLING TARGETS$165,627
U19 · FY2000 · CA
THIOREDOXIN AND ANTICANCER DRUG ACTION$150,396
R01 · FY2000 · CA
CORE--PHARMACOKINETICS /PREFORMULATION$0
U19 · FY2000 · CA
ADAPTIVE IMMUNOTHERAPY--LONG-CIRCULATING MACROMOLECULES$0
U19 · FY2000 · CA
CORE--CELL LINE AND ANIMAL TESTING$0
U19 · FY2000 · CA